Efficacy and safety of high dose intravenous ciprofloxacin in the treatment of bacterial pneumonia

International Journal of Antimicrobial Agents

Volumn 10, Issue 3, 1998, Pages 215-222

  Periti, Piero ^a   Mazzei, Teresita ^a   Elena Curti, M ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Bayer SpA Italy   (Italy)

Author keywords

Bacterial; Ciprofloxacin; Pneumonia

Indexed keywords

CIPROFLOXACIN;

ADULT; AGED; ANXIETY; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONFUSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HALLUCINATION; HEARTBURN; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHLEBITIS; PLEURA EMPYEMA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STOMACH PAIN; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PNEUMONIA, BACTERIAL;

EID: 0032143840     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(98)00039-9     Document Type: Article

References (28)

1. Periti P, Mazzei T 1-Fluorochinoloni: chemioterapia e farmacologia clinica. Farm Ter. 5(Suppl 6):1988;1-48.
2. Schacht P, Arcieri G, Branolte J et al. Worldwide clinical data on efficacy and safety of ciprofloxacin. Infection. 16(Suppl 1):1988;29-44.
3. Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS General guidelines for the evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin Infect Dis. 15(Suppl 1):1992;S62-S88.
4. Mylotte JM, Ksiazek S, Bentley DW Rational approach to the antibiotic treatment of pneumonia in elderly. Drug Aging. 4(1):1994;21-33.
5. Cunha BA The antibiotic treatment of community-acquired, athipical, and nosocomial pneumonias. Med Clin North Am. 79(3):1995;581-597.
6. Vogel F A guide to the treatment of lower respiratory tract infections. Drugs. 50(1):1995;62-72.
7. Ortqvist A Antibiotic treatment of community-acquired pneumonia in clinical practice: a European perspective. J Antimicrob Chemother. 35:1995;205-212.
8. Ramirez JA The choice of empirical antibiotic therapy for nosocomial pneumonia. J Chemother. 6(Suppl 2):1994;47-50.
9. Mason DJ, Power GM, Talsania H, Phillips I, Gant VA Antibacterial action of ciprofloxacin. Antimicrob Agents Chemother. 39(12):1995;2752-2758.
10. Ball AP, Tillotson GS Lower respiratory tract infection therapy: the role of ciprofloxacin. J Int Med Res. 23:1995;315-327.
11. Guglielmo L, Leone R et al. Aetiology and therapy of community-acquired pneumonia: a hospital study in northern Italy. Eur J Clin Pharmacol. 51:1997;437-443.
12. Wise R, Lockley RM, Webberly M, Dent J Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother. 26(2):1984;208-210.
13. Berre J, Thys JP, Husson M, Gangji D, Klastersky J Penetration of ciprofloxacin in bronchial secretions after intravenous administration. J Antimicrob Chemother. 22:1988;499-504.
14. Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH Pharamcokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 36(5):1992;993-996.
15. Schentag JJ The antimicrobial efficacy of intravenous ciprofloxacin in severe infection. Infect Med. 9(Suppl B):1992;41-57.
16. Bauernfeind A Questioning dosing regimens of ciprofloxacin. J Antimicrob Chemother. 31:1993;789-798.
17. Echols RM The selection of appropriate dosages for intravenous ciprofloxacin. J Antimicrob Chemother. 31:1993;783-787.
18. Catchpole C, Andrews JM, Woodcock J, Wise R The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg iv and 750 mg pot. J Antimicob Chemother. 33:1994;103-110.
19. Scaglione F, Mezzetti M, Arcidiacono MM, Gattei G, Fraschini F Penetration of pefloxacin and ciprfloxacin into lung tissue. J Antimicrob Chemother. 3(4):1995;557-559.
20. Davies BL, Maesen FPV Quinolones in chest infections. Antimicrob Agents Chemother. 18:1986;296-299.
21. Ball P, Tillotson G, Wilson R Chemotherapy for chronic bronchitis: controversies. Presse Med. 24:1995;189-194.
22. Chrysanthopoulos CJ, Bassaris HP Use of oral ciprofloxacin in community-acquired pneumonia. J Chemother. 1:1989;103-106.
23. Vetter N, Veist H, Orlicek M, Optual I, Weuta H. RTI Patients Treated with Ciprofloxacin and Cefalexin: A Randomized Comparison. Int Chemother Congr, Kyoto, 1985:38-95.
24. Khan FA, Basir R Sequential intravenous-oral administration of ciprofloxacin versus ceftazidime in serious bacterial respiratory tract infections. Chest. 96:1989;528-537.
25. Lode H, Wiley R, Hoffken G et al. Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrob Agents Chemother. 31:1987;1491-1496.
26. Fink MP, Snydman DR, Niederman MS et al. Treatment of severe pneumonia in hospitalized patients: results of a multi-center, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenemcilastatin. Antimicrob Agents Chemother. 38(3):1994;547-557.
27. Marklein G, German Fleroxacin Study Group. Fleroxacin versus Ciprofloxacin in the Empirical Treatment of Severe Pneumonia: iv/Oral Switch Regimen. 7th Eur Congr Clin Microbiol Infect Dis, 1995:139 (Abstr).
28. Kljucar S, Heimesaat M, von Pritzbuer E, Timm J, Bauernfeind A. A comparison of intravenous ciprofloxacin dosage regimens in severe nosocomial infections. Infect Med 1992; Suppl 'Clinical Pharmacology of IV Ciprofloxacin':58-72.